India's CDMO Sector Poised for Growth as Pharma Diversifies Away From China

The global pharmaceutical supply chain is undergoing a massive realignment as multinational drugmakers seek to reduce their reliance on China. With Indian Contract Development and Manufacturing Organisations (CDMOs) emerging as the preferred alternative, the nation is positioned to capture a significant share of the global manufacturing market.

The Strategic Shift: India as the Preferred Alternative

The movement away from Chinese manufacturing giants, such as WuXi AppTec, is no longer a future projection but a current reality. According to Sivaramakrishnan Chittor, CFO of Sai Life Sciences, the genesis of this shift began nearly two years ago. Global pharmaceutical companies have already initiated conversations to move their manufacturing footprints to India to mitigate regulatory and geopolitical risks.

The inclusion of certain entities in the 1260H list has further accelerated this diversification. Indian CDMOs are proactively responding to this landmark opportunity by scaling up operations and committing significant capital expenditure (capex) to meet the growing demand from global innovators.

Sai Life Sciences: Expanding Capacity and Revenue Mix

Sai Life Sciences is a prime example of the aggressive scaling occurring within the sector. The company has announced a massive expansion plan, intending to invest between ₹1,100 crore and ₹1,300 crore in capacity by FY27. This investment will be funded through a combination of internal accruals and debt, maintaining a healthy balance sheet.

A significant indicator of this changing landscape is the company's revenue composition. Over the last four years, the contribution from large global pharmaceutical companies has nearly doubled, rising from 28% to 49% of total revenue. This highlights a deeper integration of Indian players into the core supply chains of the world's largest drugmakers.

From Clinical Supplies to Commercial-Scale Manufacturing

One of the most critical shifts in the Indian CDMO landscape is the transition from providing clinical trial supplies to handling commercial-scale manufacturing. Historically, global pharma firms used India primarily for early-stage clinical supplies; however, there is a growing trend toward using Indian facilities for mass-market production.

Sai Life Sciences has noted a substantial increase in its late-stage development projects. The number of molecules in Phase III and pre-registration stages has grown from six to eleven, reflecting increased confidence from global innovators in India's ability to manage large-scale commercial volumes.

While the opportunity is immense, industry leaders caution that the benefits will materialize gradually. Because pharmaceutical manufacturing is heavily regulated, moving a product from one country to another involves rigorous regulatory approvals and complex product transfer timelines.

Despite these hurdles, Sai Life Sciences has maintained its robust revenue growth guidance of a 15-20% CAGR. While the immediate quarterly impact may be modest, the structural shift in the global supply chain provides a long-term growth runway for the Indian CDMO industry.

Key Takeaways

  • Strategic Diversification: Global pharma companies are actively moving manufacturing contracts from China to India to mitigate regulatory and supply chain risks.
  • Aggressive Capex: Leading Indian players like Sai Life Sciences are investing up to ₹1,300 crore to expand capacity to meet the shifting demand.
  • Commercial Evolution: The Indian CDMO sector is evolving from a provider of clinical trial supplies to a trusted partner for large-scale commercial manufacturing.